Anticancer Agent-Incorporating Polymeric Micelles: from Bench to Bedside
There are two main concepts in drug delivery systems (DDS): passive targeting and active targeting. The passive targeting system is achieved by the enhanced permeability and retention effect. Several DDS formulations have been approved worldwide. Regarding a pipeline of clinical development of anticancer agents incorporating a micelle carrier system, several clinical trials are now underway, not only in Japan but also in other countries. A phase 3 trial of NK105, a paclitaxel-incorporating micelle is now underway. In this chapter, preclinical and clinical studies of NK105; NC-6004 a cisplatin-incorporating micelle; and NC-6300, an epirubicin-incorporating micelle are reviewed.